DKSH signs agreement with Hanseo Chemical

Published: 4-Nov-2011
Ingredients Finance

To distribute glycerophosphatidylcholin (GPC) to the pharmaceutical industry worldwide


DKSH has signed an exclusive agreement with Hanseo Chemical (HanseoChem) of Korea, in which it will sell HanseoChem’s glycerophosphatidylcholin (GPC) to the pharmaceutical industry worldwide.

DKSH says it will help HanseoChem grow its business and enhance its product coverage worldwide. In addition, the chemicals and food ingredients distributor will support HanseoChem in the development and expansion of its soy derived active pharmaceutical ingredients (APIs) business.

  • Companies:
  • DKSH Performance Materials
See more

You may also like

Distribution

DKSH partners with IOI Oleo in Asia Pacific

Read more
IOI Oleo produces a range of oleochemical products for industrial applications, such as APIs and excipients for the pharmaceutical industry

Trending Articles

  1. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global customer-base, we deliver advanced ingredient solutions that enable innovation, excite today’s consumers, and contribute to public health. Rousselot is a brand of Darling Ingredients<br><br><sup>*Global Gelatin Market Insights Forecast to 2026, Calibre Research, 2020</sup>
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Distribution

DKSH partners with IOI Oleo in Asia Pacific

IOI Oleo produces a range of oleochemical products for industrial applications, such as APIs and excipients for the pharmaceutical industry
Finance

DKSH enters European distribution agreement with Omya

The distributor was reportedly chosen for its expansive network and strong service capabilities
Ingredients

Biocon collaborates to commercialise generic formulas in South East Asia

Biocon Pharma and DKSH Business Unit Healthcare have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand
Finance

Novo Nordisk Pharmatech A/S signs Asia Pacific distribution agreement with DKSH

The Danish pharma company and the Swiss market expansion expert have partnered to provide high-quality cGMP quaternary ammonium compounds in eleven markets across the region
Ingredients

DKSH signs exclusive distribution agreement with Abitec

The ingredients and specialty chemicals distributor has been selected to exclusively distribute a lipid excipient and nutritional supplement range in Thailand, Spain and Portugal
Ingredients

DKSH promotes pharmaceutical portfolio at CPhI Worldwide

DKSH, the leading market expansion services provider with a focus on Asia, showcases its pharmaceutical portfolio, innovations, solutions and concepts at CPhI Worldwide 2016 in Barcelona, Spain
Ingredients

DKSH acquires Swiss specialty chemicals distributor

The acquisition of Staerkle & Nagler will extend DKSH\'s reach into Europe
Subscribe now